OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Lathan on Community-based Cancer Evaluation Services in Underserved Patient Groups

April 13th 2023

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

Dr Cun on Molecular Classification in Endometrioid Endometrial Adenocarcinoma

April 13th 2023

Han T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.

Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models

April 13th 2023

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

Dr Randall on the Evaluation of Ganitumab Plus VDC/IE in Newly Diagnosed Metastatic Ewing Sarcoma

April 13th 2023

R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

April 13th 2023

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Dr Mahtani on Treatment Sequencing in HER2+ Metastatic Breast Cancer

April 12th 2023

Reshma Lillaney Mahtani, DO, discusses available therapies in the first-, second-, and later-line settings in patients with HER2-positive metastatic breast cancer.

Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models

April 12th 2023

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Dr Deol on CAR T-cell Therapy Selection for Patients With Relapsed/Refractory Myeloma

April 12th 2023

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr Graff on the Evaluation of Trastuzumab Deruxtecan in HER2-Zero Breast Cancer

April 12th 2023

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models

April 12th 2023

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

Dr John on the Antitumor Effects of Sulindac in an Obesity-Driven Model of Endometrial Cancer

April 12th 2023

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Dr Rini on Retreatment With Immunotherapy Following Progression in RCC

April 11th 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Dr Brunner on the Heterogeneity of Relapsed Multiple Myeloma

April 11th 2023

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and Treatment

April 11th 2023

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Dr Brastianos Breaks Down the Basics of Meningiomas

April 11th 2023

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCC

April 10th 2023

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Dr Taylor on the Integration of Tagraxofusp Into the Frontline Treatment Armamentarium for BPDCN

April 10th 2023

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Dr Sidana on CAR T-cell Therapy in Patients With R/R Myeloma and Renal Impairment

April 10th 2023

Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.

Dr Fenton on Findings from the DESTINY-Breast02 Trial in HER2+ Breast Cancer

April 10th 2023

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.